Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin for C. Difficile Recurrence Prophylaxis
NCT03200093Phase 4Terminated
- Sponsor
- Rochester General Hospital
- Start
- Jun 2017
- Primary completion
- Apr 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vancomycin in Clostridium difficile infection (CDI), sponsored by Rochester General Hospital. Started Jun 2017; status: terminated.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03200093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200093.